1. Home
  2. SAR vs PROK Comparison

SAR vs PROK Comparison

Compare SAR & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saratoga Investment Corp New

SAR

Saratoga Investment Corp New

HOLD

Current Price

$16.80

Market Cap

362.9M

Sector

Finance

ML Signal

HOLD

Logo ProKidney Corp.

PROK

ProKidney Corp.

HOLD

Current Price

$1.61

Market Cap

316.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAR
PROK
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.9M
316.0M
IPO Year
2006
2021

Fundamental Metrics

Financial Performance
Metric
SAR
PROK
Price
$16.80
$1.61
Analyst Decision
Hold
Strong Buy
Analyst Count
4
5
Target Price
★ $23.75
$7.40
AVG Volume (30 Days)
133.1K
★ 1.2M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
★ 14.34%
N/A
EPS Growth
★ 14.36
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $893,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.39
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 1075.00
52 Week Low
$17.00
$1.30
52 Week High
$24.76
$3.48

Technical Indicators

Market Signals
Indicator
SAR
PROK
Relative Strength Index (RSI) 29.78 41.68
Support Level N/A $1.56
Resistance Level $23.77 $2.01
Average True Range (ATR) 0.35 0.12
MACD 0.00 -0.04
Stochastic Oscillator 6.48 13.48

Price Performance

Historical Comparison
SAR
PROK

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About PROK ProKidney Corp.

ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.

Share on Social Networks: